Intra-articular hyaluronic acid (HA), often called viscosupplementation, is a routine line item for orthopaedic and rheumatology departments, yet the guideline position on it is divided. This article is written for hospital, clinic, doctor and pharmacy procurement teams. It reports what published guidelines and product labels state, with attribution, so buyers understand the landscape in which these injections are requested.
Why Hyaluronic Acid Injections Remain in Demand
Knee osteoarthritis is a common cause of joint pain and reduced mobility, and intra-articular injections are among the options clinicians discuss alongside oral and topical analgesics, exercise and, eventually, surgery. Hyaluronic acid preparations are labelled as viscosupplements for osteoarthritis of the knee. Hospitals and orthopaedic clinics in India therefore receive regular requests for them, even though guideline bodies do not agree on their place in care.
What the Major Guidelines Report
The table of positions below is a summary of published statements, not a recommendation from A.K. Pharma. Readers should consult the original guidelines.
- OARSI (2019): reported as a conditional recommendation for intra-articular HA in knee-only osteoarthritis, and not recommended for hip or polyarticular osteoarthritis.
- ACR / Arthritis Foundation (2019): a conditional recommendation against HA for knee osteoarthritis and a strong recommendation against it for hip osteoarthritis.
- AAOS (2021, 3rd edition): states that HA injection is not recommended for routine use in symptomatic knee osteoarthritis; the 2013 edition had carried a strong recommendation against.
- US VA/DoD (2020): a conditional recommendation for selected patients.
- NICE NG226 (2022, UK): advises not to offer hyaluronan injections for osteoarthritis.
Published reviews note that the divergence reflects differences in how panels weigh trial quality and placebo effects. One review of pharmaceutical treatments reports that, when meta-analyses are limited to trials with a low risk of bias, the effect of intra-articular HA is similar to saline injection, whereas OARSI highlights fewer long-term safety concerns for HA compared with intra-articular corticosteroids.
How the Product Categories Differ on the Label
Hyaluronic acid injections are not interchangeable. Labels differ in concentration, volume, number of injections per course and manufacturer. Examples from the A.K. Pharma catalogue include:
- Hylasto S: sodium hyaluronate 20 mg/mL, 2 mL pre-filled syringe, by Zydus.
- Hytasone: hyaluronic acid 8 mg/mL, by Intas Pharmaceuticals.
- Biovisc Ortho: hyaluronic acid intra-articular injection by Biotech Ltd.
- Monovisc: sodium hyaluronate 88 mg/4 mL, single injection.
- Durolane: sodium hyaluronate 60 mg/3 mL, single injection.
- Cingal: hyaluronic acid with triamcinolone hexacetonide, by Anika Therapeutics, marketed in India by Modi-Mundipharma.
Because Cingal contains a corticosteroid in addition to hyaluronic acid, its labelling and safety information are distinct from HA-only products and should be read separately.
Sourcing Considerations for Hospitals, Clinics and Pharmacies
For institutional buyers, the practical questions are usually about supply rather than guidelines. Common checks include authenticity and batch documentation, expiry dating, storage conditions stated on the label, pack configuration, manufacturer details and regulatory status, which can differ between products. Requirements vary by institution, so teams should confirm them with their own pharmacy and regulatory leads.
Bulk Supply Enquiries
A.K. Pharma is a Delhi-based specialty medicine distributor supplying genuine stock in bulk and wholesale quantities to hospitals, clinics, doctors and pharmacies across India. To discuss availability of hyaluronic acid injections for your institution, send a bulk or wholesale enquiry through the A.K. Pharma website.
Frequently Asked Questions
What is intra-articular hyaluronic acid (viscosupplementation)?
It is an injectable preparation of hyaluronic acid or sodium hyaluronate placed inside a joint, most commonly the knee. Product labels describe it as a viscosupplement for osteoarthritis of the knee. Specific indications, dosing and handling are set out in each product’s own labelling.
What do the major guidelines say about intra-articular hyaluronic acid in knee osteoarthritis?
Positions differ. OARSI (2019) conditionally supports it for knee-only osteoarthritis, whereas the ACR/Arthritis Foundation guideline (2019) conditionally recommends against it for the knee, and AAOS (2021) does not recommend it for routine use. NICE (NG226, 2022) advises not to offer hyaluronan injections. Procurement teams should read the guidance in full.
Why do guideline bodies reach different conclusions?
Published reviews note that evidence quality, the choice of comparator (saline placebo versus other treatments) and the weight given to small average effects vary between guideline panels. One review reports that when meta-analyses are limited to trials with a low risk of bias, the effect appears similar to saline injection.
Are all hyaluronic acid injections the same product?
No. Products differ in concentration, total dose per syringe, molecular characteristics, number of injections per course and regulatory classification. The A.K. Pharma catalogue lists, for example, Hylasto S (20 mg/mL, 2 mL syringe), Hytasone (8 mg/mL), Monovisc (88 mg/4 mL single injection) and Durolane (60 mg/3 mL single injection). Refer to each label for details.
What is Cingal and how does it differ from plain hyaluronic acid products?
Cingal is described by its manufacturer, Anika Therapeutics, as combining hyaluronic acid with triamcinolone hexacetonide, a corticosteroid, in one intra-articular injection. Because it includes a corticosteroid, its label and safety information should be reviewed separately from hyaluronic acid-only products.
Who decides whether a patient receives a viscosupplement injection?
The treating physician. A.K. Pharma is a distributor, not a healthcare provider, and does not advise on whether any product should be used. This article only reports what labels and published guidelines state.
What should a hospital pharmacy check when sourcing these injections?
Typically: valid import or marketing authorisation status, batch and expiry details, cold-chain or storage requirements stated on the label, pack size, manufacturer details and supplier documentation. Requirements vary by institution and should be confirmed with your own procurement and regulatory teams.
Does A.K. Pharma supply these products to hospitals and clinics?
A.K. Pharma, a Delhi-based specialty medicine distributor, handles bulk and wholesale enquiries from hospitals, clinics, doctors and pharmacies. Availability and pricing are provided on enquiry.
Is this article medical advice?
No. It is informational, intended for hospitals, clinics, doctors and pharmacies, and reports published label and guideline content with attribution. It is not medical advice, and treatment decisions rest solely with the treating physician.
Disclaimer: A.K. Pharma is a distributor and not a healthcare provider. This article is for informational purposes for hospitals, clinics, doctors and pharmacies, reports published label and guideline content with attribution, and is not medical advice. Treatment decisions rest solely with the treating physician. A.K. Pharma accepts bulk and wholesale enquiries only.
